<< New Zealand Trade & Enterprise takes an office in the IIB
Mayor of Auckland City turns first sod for construction of IIB bio-incubator >>
Oct 1, 2009
Founded in 2008 by Mr Stephen Wallace and Professor Russell Snell, InSyGen Therapeutics Ltd is using comparative genomics to discover novel human drug targets and develop therapeutics with an initial focus on obesity and diabetes. Co-location in the IIB provides the company with access to a broad range of relevant technology and expertise.
